Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Basic Mineral Metabolism
You have accessRestricted Access

Uremia Accelerates both Atherosclerosis and Arterial Calcification in Apolipoprotein E Knockout Mice

Ziad A. Massy, Ognen Ivanovski, Thao Nguyen-Khoa, Jesus Angulo, Dorota Szumilak, Nadya Mothu, Olivier Phan, Michel Daudon, Bernard Lacour, Tilman B. Drüeke and Martin S. Muntzel
JASN January 2005, 16 (1) 109-116; DOI: https://doi.org/10.1681/ASN.2004060495
Ziad A. Massy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ognen Ivanovski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thao Nguyen-Khoa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesus Angulo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorota Szumilak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadya Mothu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Phan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Daudon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Lacour
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tilman B. Drüeke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin S. Muntzel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Chronic renal failure (CRF) favors the development of atherosclerosis and excessive calcification of atheromatous lesions. CRF was induced in apolipoprotein E knockout (apoE−/−) mice to study (1) a possible acceleration of aortic atherosclerosis, (2) the degree and type of vascular calcification, and (3) factors involved in the calcification process. For creating CRF, 8-wk-old apolipoprotein E gene knockout (apoE−/−) mice underwent partial kidney ablation. Control animals underwent sham operation. Aortic atherosclerotic plaques and calcification were evaluated using quantitative morphologic image processing. At 6 wk after nephrectomy, CRF mice had significantly higher serum urea, cholesterol, and triglyceride concentrations than non-CRF controls. The serum levels of advanced oxidation protein products were elevated in the uremic group and were correlated with serum urea levels. Atherosclerotic lesions in thoracic aorta were significantly larger in uremic apoE−/− mice than in nonuremic controls. The relative proportion of calcified area to total surface area of both atherosclerotic lesions and lesion-free vascular tissue was increased in aortic root of uremic apoE−/− mice when compared with controls. The calcium deposits were made of hydroxyapatite and calcite crystals. In addition, plaques from uremic animals showed a significant increase in collagen content, whereas the degree of macrophage infiltration was comparable in both groups. There was no difference in mean arterial BP. These findings demonstrate that CRF aggravates atherosclerosis in apoE−/− mice. Moreover, CRF enhances arterial calcification at both atheromatous intimal sites and atheroma-free medial sites. We anticipate that this experimental model will be useful to test treatment strategies aimed at decreasing the accelerated atherosclerosis and arterial calcification in uremia

Accelerated atherosclerosis is one of the primary causes of morbidity and mortality in patients with chronic renal failure (CRF) (1,2). A high frequency of vascular lesions and events has been documented by retrospective studies and more convincingly by prospective analyses (3–6). Although classic risk factors such as advanced age, hypertension, glucose intolerance, and dyslipidemia are important in these patients, hyperphosphatemia, hypercalcemia, and/or an elevated calcium × phosphate product may play a predominant role by favoring both arterial and cardiac valve calcification and cardiovascular mortality.

In recent years, growing interest has been devoted to arterial calcification in CRF patients. Both the intima and media arterial layers are more frequently and more intensively calcified in uremic patients than in nonuremic individuals, and vascular and valvular calcification is a predictor of increased cardiovascular mortality and morbidity (7–9). In the atheromatous plaque, the most marked difference between uremic and nonuremic patients is not in its size but its composition, with a marked increase in calcium content (10,11). There are also major differences in vessel wall function in relation to media calcification, as reflected by arterial stiffening, which accounts for reduced vascular distensibility and increased vascular resistance in CRF patients (12).

It is important to identify therapeutic means to counteract or even prevent the progression of atheromatous vessel lesions and vascular calcification in CRF patients and thereby to decrease the high incidence of cardiovascular events and mortality. With this in mind, we have been involved in the creation of new experimental models to gain better insight into the mechanisms underlying the accelerated atherosclerosis and arterial calcification of CRF patients and to test possible new therapeutic strategies. However, uremic rats or mice do not easily develop atheromatous lesions. We (13) and others (14,15) reasoned that the apolipoprotein E gene knockout (apoE−/−) mouse may constitute a suitable model to address this issue. ApoE−/− mice have delayed clearance of lipoproteins, and when placed on low-cholesterol, low-fat diets, their total serum cholesterol levels reach 11 to 13 mM as a result of the accumulation of chylomicrons and cholesterol-rich VLDL remnants, as compared with 2 to 3 mM in wild-type mice. Importantly, they develop not only fatty streaks but also widespread fibrous plaques at vascular sites that are typically affected in human atherosclerosis (16). The aim of the present study was to develop an experimental model of accelerated atherosclerosis and vascular calcification in apoE−/− mice with superimposed CRF.

Materials and Methods

Animals

All experiments were performed in apoE−/− mice, which were obtained from IFFA-Credo (Lyon, France) and bred at the Necker Medical Faculty (Paris, France). The mice were housed in polycarbonate cages in a pathogen-free facility set on a 12-h light-dark cycle and given free access to water and regular laboratory chow (Harlan Teklad Global Diets). The components of the diet as listed by the manufacturer were 5.7% fat, 18.9% protein, 72.3% carbohydrates, 1.01% calcium, 0.65% phosphorus, 0.2% magnesium, and 1540 IU/kg vitamin D3. All procedures were in accordance with National Institutes of Health guidelines for the care and use of experimental animals (NIH publication No. 85-23). After sexual maturation at 4 wk of age, the mice were separated by sex and housed in groups of up to five.

Creation of CRF

At 8 wk of age, the animals were randomly assigned into a uremic group (14 female, 8 male mice) and a nonuremic control group (19 female, 6 male mice). We used a two-step procedure to create uremia. Briefly, we applied cortical electrocautery to the right kidney through a 2-cm flank incision and performed left total nephrectomy through a similar incision 2 wk later as described by Gagnon et al. (17). In an initial series aimed at inducing severe reductions in renal function, we observed a 100% mortality of apoE−/− mice at 24 h after contralateral kidney ablation, although 12 of 16 C57BL/6J mice survived for several weeks after the same degree of renal mass reduction (unpublished personal observations). Because the intensity of electrocoagulation determines the degree of CRF, we then aimed to produce a more moderate reduction in renal function and obtained serum urea concentrations between 25 and 30 mM. Control animals received sham operation that included decapsulation of both kidneys. Special care was taken to avoid damage to the adrenals. At 6 wk after surgery, mice were killed by exsanguination under ketamine/xylazine anesthesia (100 mg/kg and 20 mg/kg) in the nonfasting state.

Biochemical Serum Determinations

Blood was collected from the abdominal aorta into chilled dry tubes and spun in a refrigerated centrifuge, and serum was stored at −80°C. Serum levels of urea, total cholesterol, and triglycerides were assessed using a Hitachi 917 autoanalyzer (Roche, Meylan, France). Serum levels of advanced oxidation protein products (AOPP) were measured by spectrophotometry with a microplate reader as described previously (18). In separate groups of male and female apoE−/−- mice (18 uremic mice and 24 control mice), we measured serum calcium and phosphorus with a Hitachi 917 autoanalyzer and mouse intact parathyroid hormone (iPTH) using a two-site ELISA (Immutopics, Quidel, France).

Quantification of Atheromatous Lesions in Aorta

For the aortic root sections, the vasculature was perfused with sterile PBS, and the ventricular edge and approximately 1 mm of the aortic root were immediately dissected under a microscope and cryomounted in optimal cutting temperature embedding medium. Cryosections, cut in 10-μm-thick slices, were collected and numbered from the appearance of the first cusp (point 0). Sections at 200-, 400-, 600-, and 800-μm distances from the cusps were stained with oil red-O, counterstained with hematoxylin, and mounted under coverslips. For the thoracic aorta sections, the vasculature was perfused and aortic sections from the left subclavian artery to the last intercostal artery branch were dissected and cryomounted. Cryosections, cut in 10-μm thicknesses, were numbered beginning at 4 mm distal from the left subclavian artery (point 0). Sections at 100-, 200-, 300-, and 400-μm distances from point 0 were stained as described above. The stained cryosections were magnified at ×5, and the images were captured on a microcomputer equipped with a program developed in Quips language that permitted quantification of the lesions (Leica, Cambridge, UK). The cross-section surface area of the vessel and cross-section surface area of the lesion were assessed.

Quantitative and Qualitative Evaluation of Aorta Calcification

Vascular calcifications in aortic root were evaluated by von Kossa staining in cryosections of aortic tissue. Briefly, the cryosections were placed in 5% silver nitrate solution (Sigma Aldrich, St. Louis, MO) for 30 min in darkness. Then, they were put in revelator solution (Kodak) for 5 min and fixed in 5% sodium-thiosulfate solution for another 5 min. Finally, they were stained with 2% eosin. Calcium deposits appeared in black on a bright red-colored surrounding tissue. We developed morphologic image processing algorithms for computer-assisted automated quantitative measurement of calcification from aortic sections (19), revealed from the von Kossa’s silver nitrate staining. Calcium deposits were measured inside and outside atherosclerotic lesions, reflecting atherosclerotic and medial calcium deposits, respectively. Data were expressed as the relative proportion of calcified area to total surface area of either the inside or the outside of atherosclerotic lesions and as the size of calcification granules on either surface, as described previously (19).

To perform additional qualitative characterization of vascular calcification type in CRF apoE−/− mice, we performed Fourier transform infrared (FTIR) spectroscopy of the vascular tissue (Bruker vector 22, Bruker A590 microscope) (20).

Quantification of Monocyte-Macrophage Infiltration and Collagen Content in Aortic Lesions

Monocyte-macrophages (MOMA) were detected in atherosclerotic lesion by immunostaining as described previously (21). Briefly, aortic sections were incubated with 10% normal goat serum for 30 min at room temperature, washed in PBS, and incubated with a primary rat monoclonal antibody against mouse macrophages (clone MOMA-2; BioSource International, Camarillo, CA) for 1 h at room temperature. The secondary antibody was a biotin-horseradish peroxidase-conjugated goat anti-rat IgG (Vector Laboratories, Biovalley, Marne la Vallée, France). Immunostainings were visualized after incubation with a peroxidase detection system (Vectastain ABC kit, Vector Laboratories) using 3-amino 9-ethyl carbazole (Sigma Aldrich) as substrate. At least four sections per animal were analyzed for each immunostaining.

The lesion collagen content was determined by staining with Sirius red (21). The image was captured on a microcomputer equipped with Histolab software (Microvision Instruments, Envy, France) and analyzed by computerized image analysis measuring the relative area/density in 12 continuous fields in each Sirius red–stained section. Because collagen content may depend on the size of the lesions, only large lesions were examined for determination of content.

BP Measurements

In a separate set of CRF apoE−/− mice (3 female, 3 male mice) and age-matched nonuremic apoE−/− control mice (3 female, 3 male mice), we measured mean arterial BP at the day of killing using direct intra-arterial recording as described previously (22). Briefly, the mice were anesthetized with ketamine/xylazine (100 mg/kg and 20 mg/kg, intraperitoneally), and a PE50 catheter, stretched to reduce the tip diameter, was inserted into the abdominal aorta. The catheter was filled with heparinized saline (20 U/ml), and the distal end was attached to a BP transducer (Gould pressure processor). After a 5-min stabilization period, three BP tracings were obtained, and BP was averaged from the three measurements.

Statistical Analyses

Data were analyzed by ANOVA, linear regression analyses, and unpaired t test, as appropriate. Results were expressed as means ± SEM. Differences between groups were considered significant at P < 0.05.

Results

Body Weight and Serum Biochemistry

Body weight did not differ between the uremic and nonuremic apoE−/− mice throughout the study (24.4 ± 1.3 versus 23.5 ± 1.2 g, respectively). Serum urea levels were used to assess renal function. At 6 wk after surgery, serum urea concentrations in CRF mice increased by 225% above baseline and tended to be stable, with minimal variations during the 6-wk period (Figure 1A). Serum total cholesterol and triglyceride concentrations were significantly higher in CRF mice compared with non-CRF controls (Figure 1, B and C). Serum AOPP levels were significantly higher in CRF animals than in controls (Figure 1D). By linear regression analysis, AOPP values were closely associated with serum urea values (r2 = 0.71, P < 0.001; Figure 2).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Serum concentrations of urea (A), total cholesterol (B), triglycerides (C), and advanced oxidation protein products (AOPP; D). Apolipoprotein E-deficient (apoE−/−) mice were subjected to either sham operation (control mice) or a two-step creation of chronic renal failure (CRF). CRF mice, n = 22; control mice, n = 25. EC, electrocoagulation of right renal cortex; Nx, left total nephrectomy. P < 0.001 ANOVA between groups. *P < 0.05 Fischer post hoc least significant difference test between control and CRF.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Correlation between serum AOPP and serum urea in the CRF and control apoE−/− groups collapsed together. CRF mice, n = 22; control mice, n = 25.

Uremic animals had higher serum calcium and phosphate concentrations (P < 0001, P < 0.05, respectively; Table 1) and higher serum iPTH values (P < 0.05; Table 1). Mean arterial BP was comparable between the groups (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Effect of CRF on MAP, serum urea, calcium, phosphorus, Ca × P product, and iPTH in 16-wk-old apoE−/− mice, 6 wk after creation of CRFa

Atheromatous Lesions of Aorta

Six weeks of CRF significantly increased aortic plaque area fraction in thoracic aorta in CRF mice compared with controls (P < 0.04; Figure 3). The impact of uremia on atherosclerosis in the aortic root seemed to be less pronounced because lesion sizes at this site were comparable in the two groups (Table 2). Also in the aortic root, lesions were larger and more advanced in female than in male apoE−/− mice (P = 0.03; data not shown).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Atherosclerotic lesion cross-section area in thoracic aorta of control apoE−/− and CRF apoE−/−mice. CRF mice, n = 22; control mice, n = 25. Data are means ± SEM.

View this table:
  • View inline
  • View popup
Table 2.

Effect of CRF on plaque progression and composition in aortic root of 16-wk-old apoE−/− mice, 6 wk after creation of CRFa

Aortic Calcification, Total Collagen Content, and MOMA Infiltration

CRF apoE−/− mice had significantly larger areas of atheromatous and medial calcification than nonuremic apoE−/− mice (Table 2, Figure 4). Moreover, intimal and medial calcification sizes were increased in CRF mice compared with controls, although this difference reached statistical significance only in the intima. There were no correlations between intimal or medial calcification area or size and serum calcium, phosphorus, calcium × phosphorus product, cholesterol, triglycerides, AOPP, or atherosclerotic lesion area (data not shown). However, a significant correlation was observed in uremic mice between intimal and medial calcification area (r2 = 0.94, P < 0.001) and between intimal and medial calcification sizes (r2 = 0.66, P < 0.001), suggesting a link between atherosclerotic and medial vascular calcification.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Representative images of aorta root sections of control apoE−/− and CRF apoE−/− mice. (A) Von Kossa silver nitrate staining (calcification in black). (B) Morphologic image processing (calcification in red) (C) Representative images of aortic root of CRF apoE−/− mouse showing a higher magnification (×10) of the object after 2% eosin (1) as well as after 2% eosin and von Kossa staining (2). M, media; I, intima; L, lumen.

FTIR spectroscopy confirmed a significant overall increase of mineral density in the plaques of CRF apoE−/− mice compared with control mice. Moreover, it showed that the calcium deposits were made of hydroxyapatite (carbapatite) and calcite (calcium carbonate anhydrous) crystals in both the intimal and medial lesion sites. The calcium deposits in the intimal lesions were frequently co-localized with the presence of cholesterol crystals (Figure 5).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Fourier transformed infrared spectroscopy of aortic tissue of an apoE−/− mouse with CRF and a control apoE−/− mouse, respectively, showing an overall increase in mineral density (calcite and hydroxyapatite peaks) in the plaques of CRF apoE−/− mice. Typical peaks of calcite are seen at 1410, 876, and 719 cm−1 and those of hydroxyapatite at 1035 and 957 cm−1, respectively.

Finally, uremia was associated with a 38% increase in plaque collagen content (Table 2). However, the percentage of lesion cross-section area occupied by macrophages, as revealed by MOMA-2 staining, was comparable between the two groups (Table 2).

Discussion

The present findings lend support to the controversial view that the uremic state results in accelerated atherosclerosis. We found that 6 wk of CRF increased plaque progression in the thoracic aorta of CRF apoE−/− mice compared with controls. This finding is in agreement with two other recent reports in uremic apoE−/− mice (14,15) and extend the results by showing that CRF increased plaque progression as early as 6 wk of uremia duration. It is of interest that Bro et al. (23) recently reported lack of lesion formation in male uremic mice at 2 wk of uremia.

In addition to accelerated atherosclerosis, we found that CRF mice had significant increases in aortic vessel calcification. To the best of our knowledge, this is the first report of vascular calcification in the apoE−/− model of atherosclerosis combined with CRF. The uremic state is associated with numerous metabolic abnormalities and endocrine disturbances, including abnormalities in calcium and phosphate metabolism and an inflammatory syndrome. These dysfunctions occur early in the course of CRF and contribute to the development and progression of vascular calcification and atherosclerosis. Severe calcifications of both the medial wall layer and the intima have been reported frequently in uremic patients (11,24). Although it is possible at present to quantify arterial calcifications in humans with electron-beam computed tomography or spiral computed tomography, these noninvasive techniques do not allow one to distinguish intima from media calcification and to study their respective progression. Animal studies provide the possibility of separately assessing the progression of vessel calcification at different anatomic sites to determine whether CRF differentially modifies the extent of intima and media calcification and of testing new strategies aimed at arresting the progression or causing regression of vascular calcium deposits.

Enhanced medial calcification was observed previously in uremic rats (25) and rabbits (26). However, in addition to medial calcification, calcification of the intima was reported in only one recent study that examined CRF-induced atherosclerosis in the LDL receptor–deficient (LDLR−/−) mouse (27). In this study, vessel wall calcification was evaluated only semiquantitatively. In contrast, we were able for the first time to quantify calcium deposits in the intimal plaque area and media of aortic tissue by using a technique recently established in our laboratory (19). In both the intimal and medial layer of the aorta, we found a significant increase in calcified area in uremic mice compared with nonuremic controls. Surprising is that two recent reports that examined CRF in apoE−/− mice (14,15) failed to observe calcification in the aortic wall despite a longer duration of uremia (12 and 22 wk, respectively). One possible explanation for this disparity is differences in the dietary regimen. Our diet contained a higher calcium/phosphate ratio (1.6) than those of the two previous studies (1.0 and 1.3 respectively), and this ratio has been shown to be an important factor for the regulation of intestinal calcium absorption (28). In addition, our dietary vitamin D3 content (1540 IU/kg) was almost three times higher than in the previous work (600 IU/kg). In the present study, serum calcium, phosphorus, and iPTH concentrations were higher in CRF than in non-CRF apoE−/− mice. All of these parameters are well-known factors that favor soft tissue calcification in patients with CRF. However, the degree of severity of calcium and phosphorus was comparable between our CRF apoE−/− mice and those in the former two studies. It is possible that differences in dietary factors such as relative amounts of protein, carbohydrate, and lipid, as well as their composition, may have contributed to the development of vascular calcification in our experimental model. However, we found that male CRF apoE−/− mice had slower progression of vascular calcification than their female counterparts (data not shown). This could have contributed to the difference in vascular calcification between the present study and previous studies when male mice were used exclusively (14,15). Of note, sex differences of proteinuria (29), atheroma progression (30), and atheromatous lesion calcification (31) have also been reported in apoE−/− mice with normal renal function.

To characterize further arterial calcification in apoE−/− mice, we used FTIR spectroscopy and found that calcium deposits in both the intimal lesions and medial layers were made of hydroxyapatite and calcite crystals. Our data are in line with previous data in human coronary arteries in which calcified plaques of ESRD patients contained only hydroxyapatite and calcium phosphate but not calcium oxalate crystals (10). That calcification was increased in both the intima and the media is compatible with CRF-associated disturbances, leading to an increase in soft tissue calcification in general. Hyperphosphatemia may play an important role, in addition to hypercalcemia (32). However, a definitive conclusion about the respective roles of hyperphosphatemia and hypercalcemia in CRF apoE−/− mice can be drawn only from an intervention designed to modify their levels separately and to measure subsequently changes in vascular calcification. Of note, a recent randomized clinical trial in dialysis patients showed prevention of the progression of vascular calcification by the non-calcium-containing binder sevelamer, in contrast to calcium-containing phosphate binders. However, there was no distinction between aortic and coronary artery localization in the media and the intima, respectively (33).

Additional factors other than excess calcium or phosphate likely participate in the pathogenesis of vascular calcification (34). The intimal lesions were frequently co-localized with cholesterol crystals. The increase in serum total cholesterol in CRF apoE−/− mice compared with control mice may be such a factor contributing to accelerated atherosclerosis and vascular calcification (32).

Oxidative stress and inflammation have been recognized to play a central role in the pathogenesis of cardiovascular disease in uremia (35). In the present study, CRF apoE−/− mice had an increase in serum AOPP, which is a marker of chlorinated-oxidative stress. However, we did not find correlations between intimal or medial calcification area or size and AOPP. Buzello et al. (14) and Bro et al. (15) observed an increase in nitrotyrosine expression (a marker of nitrosative-oxidative stress) in the aortic wall of CRF apoE−/− mice, although they did not report a correlation. This increase might point to the possible importance of nitrosative stress in the accelerated atherosclerosis of CRF apoE−/− mice. In dialysis patients, however, chlorinated stress seems to prevail, because we and others did not observe an increase of plasma nitrotyrosine levels, whereas high concentrations of plasma chlorinated markers were present (36,37). Surprising is that a protective role for myeloperoxidase-generated reactive intermediates has been observed even in murine atherosclerosis (38), in agreement with possible difference between murine and human atherosclerosis development with regard to the involvement of chlorinated stress.

At present, there is only limited information on the impact of uremia on atherosclerotic plaque composition. In the present experimental setting, the atheromatous lesions of uremic animals exhibited a marked increase in collagen content as well as high calcite and hydroxyapatite content, although there was no evidence of increased infiltration by inflammatory cells. It remains unclear to which extent arterial wall inflammation contributes to the enhanced atherosclerosis and calcium deposition observed in the CRF apoE−/− mice. It is interesting that a recent study in men (albeit not in women) failed to show a correlation between circulating C-reactive protein, a potent marker of inflammation, and coronary artery calcification, which is an index of atherosclerosis, suggesting that the widely accepted association between inflammation and atherosclerosis and/or calcification is more complex than was generally thought (39). However, C-reactive protein serum concentration was observed to be inversely related to that of fetuin-A (a negative acute-phase protein and an extracellular calcium regulatory molecule), and low fetuin-A concentrations in sera were found to be associated with enhanced all-cause and cardiovascular mortality in chronic hemodialysis patients (40). This complex relationship is currently under investigation in our laboratory. Obviously, other proteins with high calcium affinity such as bone matrix proteins also play an important role, both systemically and locally, in the determination of vascular calcium deposition (11,41). The observed accumulation of collagen in plaques might also have contributed.

At present, the excessive cardiovascular mortality in CRF patients continues to represent an unmet challenge. Various approaches to reduce premature atherosclerosis and vascular calcification in such patients will need to be tested to evaluate their efficacy and practicability. A major limiting factor in uremia-accelerated vascular calcification has been the lack of appropriate animal models. We propose that the CRF apoE−/− mouse, in addition to the CRF LDLR−/− mouse, provides a suitable model to analyze the different molecular and cellular mechanisms responsible for this serious complication of chronic kidney disease. Moreover, it may provide a useful tool for the evaluation of new therapeutic strategies aimed at reducing the accelerated atherosclerosis and vascular calcification associated with uremia.

Acknowledgments

O.I. was funded by a grant from Egide Foundation (Paris, France).

This study was presented as an abstract at the World Congress of Nephrology, June 8–12, 2003, Berlin, Germany.

We thank Nadine Bouby, PhD, Inserm Unit 367, Paris, for use of a BP recording device; Ziad Mallat, MD, PhD, INSERM Unit 541, Lariboisière Hospital (Paris, France) and Antonino Nicoletti, PhD, INSERM unit 430, Broussais Hospital (Paris, France), for expert technical advice.

Footnotes

  • Drs. Ziad A. Massy and Ognen Ivanovski contributed equally to this article.

  • © 2005 American Society of Nephrology

References

  1. ↵
    Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9: S16–23, 1998
  2. ↵
    London GM, Drueke TB: Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51: 1678–1695, 1997
    OpenUrlCrossRefPubMed
  3. ↵
    Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212–2217, 2002
    OpenUrlAbstract/FREE Full Text
  4. Kato A, Takita T, Maruyama Y, Kumagai H, Hishida A: Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int 64: 1472–1479, 2003
    OpenUrlCrossRefPubMed
  5. O’Hare AM, Glidden DV, Fox CS, Hsu CY: High prevalence of peripheral arterial disease in persons with renal insufficiency: Results from the National Health and Nutrition Examination Survey 1999–2000. Circulation 109: 320–323, 2004
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899–1911, 1999
    OpenUrlCrossRefPubMed
  7. ↵
    Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 14: 159–168, 2003
    OpenUrlAbstract/FREE Full Text
  8. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938–942, 2001
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695–701, 2002
    OpenUrlCrossRefPubMed
  10. ↵
    Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218–223, 2000
    OpenUrlCrossRefPubMed
  11. ↵
    Moe SM, O’Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638–647, 2002
    OpenUrlCrossRefPubMed
  12. ↵
    Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014–1021, 2000
    OpenUrlCrossRefPubMed
  13. ↵
    Muntzel MMZ, Ruellan N, Descamps-Latscha B, Lacour B, Drueke TB: Chronic renal failure increases oxidative stress and accelerates atherosclerosis in apolipoprotein-E knock-out (EKO) mice [Abstract]. Nephrol Dial Transplant 17[Suppl 1]: 46, 2002
    OpenUrl
  14. ↵
    Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K: The apolipoprotein e knockout mouse: A model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14: 311–316, 2003
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Bro S, Bentzon JF, Falk E, Andersen CB, Olgaard K, Nielsen LB: Chronic renal failure accelerates atherogenesis in apolipoprotein e-deficient mice. J Am Soc Nephrol 14: 2466–274, 2003
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71: 343–353, 1992
    OpenUrlCrossRefPubMed
  17. ↵
    Gagnon RF, Gallimore B: Characterization of a mouse model of chronic uremia. Urol Res 16: 119–126, 1988
    OpenUrlCrossRefPubMed
  18. ↵
    Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304–1313, 1996
    OpenUrlCrossRefPubMed
  19. ↵
    Angulo J, Nguyen-Khoa T, Massy ZA, Drueke TB, Serra J: Morphological quantification of aortic calcification from low magnification images. Image Anal Stereol 22: 81–89, 2003
    OpenUrl
  20. ↵
    Dao NG, Daudon M: Infrared and Raman Spectra of Calculi, Paris, Elsevier, 1997
  21. ↵
    Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R, Fradelizi D, Tedgui A: Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 89: 930–934, 2001
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Meneton P, Ichikawa I, Inagami T, Schnermann J: Renal physiology of the mouse. Am J PhysiolRenal Physiol 278: F339–F351, 2000
    OpenUrlPubMed
  23. ↵
    Bro S, Moeller F, Andersen CB, Olgaard K, Nielsen LB: Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. J Am Soc Nephrol 15: 1495–1503, 2004
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R 3rd: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 66: 790–796, 1979
    OpenUrlCrossRefPubMed
  25. ↵
    Ejerblad S, Eriksson I, Johansson H: Uraemic arterial disease. An experimental study with special reference to the effect of parathyroidectomy. Scand J Urol Nephrol 13: 161–169, 1979
    OpenUrlCrossRefPubMed
  26. ↵
    Tvedegaard E: Arterial disease in chronic renal failure—an experimental study in the rabbit. Acta Pathol Microbiol Immunol Scand Suppl 290: 1–28, 1987
    OpenUrlPubMed
  27. ↵
    Davies MR, Lund RJ, Hruska KA: BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 14: 1559–1567, 2003
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Masuyama R, Nakaya Y, Katsumata S, Kajita Y, Uehara M, Tanaka S, Sakai A, Kato S, Nakamura T, Suzuki K: Dietary calcium and phosphorus ratio regulates bone mineralization and turnover in vitamin D receptor knockout mice by affecting intestinal calcium and phosphorus absorption. J Bone Miner Res 18: 1217–1226, 2003
    OpenUrlCrossRefPubMed
  29. ↵
    Ivanovski O, Nguyen-Khoa T, Phan O, Massy ZA: Could proteinuria evaluation be helpful in predicting renal progression in apolipoprotein E-deficient (E−/−) mice with chronic renal failure? Nephrol Dial Transplant 19: 1013–1014; author reply 1014, 2004
    OpenUrlCrossRefPubMed
  30. ↵
    Caligiuri G, Nicoletti A, Zhou X, Tornberg I, Hansson GK: Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis 145: 301–308, 1999
    OpenUrlCrossRefPubMed
  31. ↵
    Qiao JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Demer LL, Lusis AJ: Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb 14: 1480–1497, 1994
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Moe SM, Chen NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95: 560–567, 2004
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245–252, 2002
    OpenUrlCrossRefPubMed
  34. ↵
    Moe SM, Duan D, Doehle BP, O’Neill KD, Chen NX: Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63: 1003–1011, 2003
    OpenUrlCrossRefPubMed
  35. ↵
    Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524–1538, 2002
    OpenUrlCrossRefPubMed
  36. ↵
    Massy ZA, Borderie D, Nguyen-Khoa T, Drueke TB, Ekindjian OG, Lacour B: Increased plasma S-nitrosothiol levels in chronic haemodialysis patients. Nephrol Dial Transplant 18: 153–157, 2003
    OpenUrlCrossRefPubMed
  37. ↵
    Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW: Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 31: 1163–1169, 2001
    OpenUrlCrossRefPubMed
  38. ↵
    Brennan ML, Anderson MM, Shih DM, Qu XD, Wang X, Mehta AC, Lim LL, Shi W, Hazen SL, Jacob JS, Crowley JR, Heinecke JW, Lusis AJ: Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 107: 419–430, 2001
    OpenUrlCrossRefPubMed
  39. ↵
    Reilly MP, Wolfe ML, Localio AR, Rader DJ: C-reactive protein and coronary artery calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA). Arterioscler Thromb Vasc Biol 23: 1851–1856, 2003
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Ketteler M, Bongartz P, Westenfeld R, Ernst Wildberger J, Horst Mahnken A, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 361: 827–833, 2003
    OpenUrlCrossRefPubMed
  41. ↵
    Shanahan CM, Proudfoot D, Tyson KL, Cary NR, Edmonds M, Weissberg PL: Expression of mineralisation-regulating proteins in association with human vascular calcification. Z Kardiol 89[Suppl 2]: 63–68, 2000
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 16 (1)
Journal of the American Society of Nephrology
Vol. 16, Issue 1
1 Jan 2005
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Uremia Accelerates both Atherosclerosis and Arterial Calcification in Apolipoprotein E Knockout Mice
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Uremia Accelerates both Atherosclerosis and Arterial Calcification in Apolipoprotein E Knockout Mice
Ziad A. Massy, Ognen Ivanovski, Thao Nguyen-Khoa, Jesus Angulo, Dorota Szumilak, Nadya Mothu, Olivier Phan, Michel Daudon, Bernard Lacour, Tilman B. Drüeke, Martin S. Muntzel
JASN Jan 2005, 16 (1) 109-116; DOI: 10.1681/ASN.2004060495

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Uremia Accelerates both Atherosclerosis and Arterial Calcification in Apolipoprotein E Knockout Mice
Ziad A. Massy, Ognen Ivanovski, Thao Nguyen-Khoa, Jesus Angulo, Dorota Szumilak, Nadya Mothu, Olivier Phan, Michel Daudon, Bernard Lacour, Tilman B. Drüeke, Martin S. Muntzel
JASN Jan 2005, 16 (1) 109-116; DOI: 10.1681/ASN.2004060495
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Parathyroid Hormone 7-84 Induces Hypocalcemia and Inhibits the Parathyroid Hormone 1-84 Secretory Response to Hypocalcemia in Rats with Intact Parathyroid Glands
  • Fibroblast Growth Factor 23 Is a Counter-Regulatory Phosphaturic Hormone for Vitamin D
  • Increased Parathyroid Hormone Gene Expression in Secondary Hyperparathyroidism of Experimental Uremia Is Reversed by Calcimimetics: Correlation with Posttranslational Modification of the Trans Acting Factor AUF1
Show more Basic Mineral Metabolism

Cited By...

  • Myeloperoxidase-derived oxidants damage artery wall proteins in an animal model of chronic kidney disease-accelerated atherosclerosis
  • Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling
  • T Cell CX3CR1 Mediates Excess Atherosclerotic Inflammation in Renal Impairment
  • Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis
  • Iron Sucrose Accelerates Early Atherogenesis by Increasing Superoxide Production and Upregulating Adhesion Molecules in CKD
  • Increased Atherosclerotic Lesion Formation and Vascular Leukocyte Accumulation in Renal Impairment Are Mediated by Interleukin-17A
  • PA21, a New Iron-Based Noncalcium Phosphate Binder, Prevents Vascular Calcification in Chronic Renal Failure Rats
  • Nonculprit Coronary Plaque Characteristics of Chronic Kidney Disease
  • Molecular Imaging Insights Into Early Inflammatory Stages of Arterial and Aortic Valve Calcification
  • Vascular Calcification in Chronic Renal Failure: What Have We Learned From Animal Studies?
  • Lipoprotein(a) accelerates atherosclerosis in uremic mice
  • Multimodal CARS microscopy determination of the impact of diet on macrophage infiltration and lipid accumulation on plaque formation in ApoE-deficient mice
  • Farnesoid X Receptor Activation Prevents the Development of Vascular Calcification in ApoE-/- Mice With Chronic Kidney Disease
  • CKD Accelerates Development of Neointimal Hyperplasia in Arteriovenous Fistulas
  • Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease
  • Mechanisms of Aortic and Cardiac Dysfunction in Uremic Mice With Aortic Calcification
  • Media Calcification and Intima Calcification Are Distinct Entities in Chronic Kidney Disease
  • Vitamin D Receptor Activators Can Protect against Vascular Calcification
  • RISK FACTORS FOR CARDIOVASCULAR DISEASE IN PATIENTS UNDERGOING PERITONEAL DIALYSIS
  • Inhibition of the Renin-Angiotensin System Abolishes the Proatherogenic Effect of Uremia in Apolipoprotein E-Deficient Mice
  • Lipid Changes and Statins in Chronic Renal Insufficiency
  • Cross-Talk between the Kidney and the Cardiovascular System
  • Uremia-Specific Effects in the Arterial Media During Development of Uremic Atherosclerosis in Apolipoprotein E-Deficient Mice
  • Stem Cells of Aging Donors--Insufficient Capacity to Repair Causes Progression of Atherosclerosis in the Recipient: Molecular Evidence for Arterial Repair in Atherosclerosis. Proc Natl Acad Sci U S A 102: 16789-16794, 2005
  • Antiatherogenic Effects of Angiotensin Receptor Antagonism in Mild Renal Dysfunction
  • Ferumoxtran-10-Enhanced MRI of the Hypercholesterolemic Rabbit Aorta: Relationship Between Signal Loss and Macrophage Infiltration
  • Edema and Congestive Heart Failure from Thiazolidone Insulin Sensitizers--Excess Sodium Reabsoption in the Collecting Duct: Collecting Duct-Specific Deletion of Peroxisome Proliferator-Activated Receptor {gamma} Blocks Thiazolidinedione-Induced Fluid Retention. Proc Nat Acad Sci U S A 102: 9406-9411, 2005
  • Sevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E-Deficient Mice
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire